Citation Impact
Citing Papers
Loss of 53BP1 Causes PARP Inhibitor Resistance in Brca1 -Mutated Mouse Mammary Tumors
2012
Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial
2014 Standout
CTLA-4 Blockade Synergizes Therapeutically with PARP Inhibition in BRCA1-Deficient Ovarian Cancer
2015
A Phase II, Randomized, Placebo-Controlled Study of Vismodegib as Maintenance Therapy in Patients with Ovarian Cancer in Second or Third Complete Remission
2012
Alpelisib for PIK3CA -Mutated, Hormone Receptor–Positive Advanced Breast Cancer
2019 Standout
Crippling life support for SARS-CoV-2 and other viruses through synthetic lethality
2020 StandoutNobel
Phase II, Open-Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of Olaparib, a Poly (ADP-Ribose) Polymerase Inhibitor, and Pegylated Liposomal Doxorubicin in Patients With BRCA1 or BRCA2 Mutations and Recurrent Ovarian Cancer
2011
BMN 673, a Novel and Highly Potent PARP1/2 Inhibitor for the Treatment of Human Cancers with DNA Repair Deficiency
2013
PARP inhibitors: Synthetic lethality in the clinic
2017 StandoutScience
Targeted therapies for breast cancer
2011
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
2017 Standout
Triple negative breast cancer: unmet medical needs
2010
The Ensembl Variant Effect Predictor
2016 Standout
Triple-negative breast cancer: disease entity or title of convenience?
2010
Cancer–stromal cell interactions mediated by hypoxia-inducible factors promote angiogenesis, lymphangiogenesis, and metastasis
2012 StandoutNobel
Breast cancer
2019 Standout
Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer
2012
Triple-negative breast cancer molecular subtyping and treatment progress
2020 Standout
Imaging Therapeutic PARP Inhibition In Vivo through Bioorthogonally Developed Companion Imaging Agents
2012
Changing Concepts of Hormone Receptor–Positive Advanced Breast Cancer Therapy
2012
Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial
2014
A view on drug resistance in cancer
2019 StandoutNature
Breast cancer
2016 Standout
Two decades beyond BRCA1/2: Homologous recombination, hereditary cancer risk and a target for ovarian cancer therapy
2015
Targeted Therapy for Breast Cancer
2013
Cancer nanomedicine: progress, challenges and opportunities
2016 Standout
Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework
2014 Standout
Poor Interobserver Reproducibility in the Diagnosis of High-grade Endometrial Carcinoma
2013
BRCAness revisited
2016
PARP inhibitor combination therapy
2016
Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial
2016
Pancreatic cancer
2020 Standout
PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directions
2016
Ovarian cancer
2014 Standout
Appraising iniparib, the PARP inhibitor that never was—what must we learn?
2013
A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation
2013
Olaparib: First Global Approval
2015
Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future
2017 Standout
Modulation of oxidative stress as an anticancer strategy
2013 Standout
Results of a phase II study comparing three dosing regimens of fulvestrant in postmenopausal women with advanced breast cancer (FINDER2)
2010
Advances in using PARP inhibitors to treat cancer
2012
Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease
2016 Standout
Influence of tumour micro-environment heterogeneity on therapeutic response
2013 StandoutNature
Pancreatic cancer
2016 Standout
Triple-negative breast cancer: treatment challenges and solutions
2016
Advances in the treatment of advanced oestrogen-receptor-positive breast cancer
2016
Loss of HOXD10 expression induced by upregulation of miR-10b accelerates the migration and invasion activities of ovarian cancer cells
2013
miR200-regulated CXCL12β promotes fibroblast heterogeneity and immunosuppression in ovarian cancers
2018
Augmentation of Response to Chemotherapy by microRNA-506 Through Regulation of RAD51 in Serous Ovarian Cancers
2015
Cediranib, a pan-VEGFR inhibitor, and olaparib, a PARP inhibitor, in combination therapy for high grade serous ovarian cancer
2016
Hypoxia-inducible factor–dependent breast cancer–mesenchymal stem cell bidirectional signaling promotes metastasis
2012 StandoutNobel
Single-cell and subcellular pharmacokinetic imaging allows insight into drug action in vivo
2013
Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study
2014
A Good Drug Made Better: The Fulvestrant Dose-Response Story
2014
Integrated genomic characterization of endometrial carcinoma
2013 StandoutNature
Androgen Receptor Biology in Triple Negative Breast Cancer: a Case for Classification as AR+ or Quadruple Negative Disease
2015
Efficacy and safety of olaparib monotherapy in germline BRCA1 / 2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy
2015
Unraveling the therapeutic potential of the Hedgehog pathway in cancer
2013 Standout
Current trends and challenges in sample preparation for global metabolomics using liquid chromatography–mass spectrometry
2012
Mechanisms of resistance to therapies targeting BRCA-mutant cancers
2013
MicroRNA therapeutics: towards a new era for the management of cancer and other diseases
2017 Standout
PARP Inhibitor Treatment in Ovarian and Breast Cancer
2011
Adeno-associated virus vector as a platform for gene therapy delivery
2019 Standout
Matching chelators to radiometals for radiopharmaceuticals
2013 Standout
DNA repair dysregulation from cancer driver to therapeutic target
2012
Macrophages as regulators of tumour immunity and immunotherapy
2019 Standout
Synthetic lethality: the road to novel therapies for breast cancer
2016
The ChEMBL database in 2017
2016 Standout
Therapeutic potential of PARP inhibitors for metastatic breast cancer
2011
Recent progress in the diagnosis and treatment of ovarian cancer
2011
Synthetic lethality and cancer
2017
Palbociclib and Letrozole in Advanced Breast Cancer
2016 Standout
Genome-wide transcriptome profiling of homologous recombination DNA repair
2014
Efficient generation of mouse models of human diseases via ABE- and BE-mediated base editing
2018 Standout
The PI3K Pathway in Human Disease
2017 Standout
Metastatic colonization by circulating tumour cells
2016 StandoutNature
VarScan 2: Somatic mutation and copy number alteration discovery in cancer by exome sequencing
2012 Standout
VarDict: a novel and versatile variant caller for next-generation sequencing in cancer research
2016
Using sulfuramidimidoyl fluorides that undergo sulfur(vi) fluoride exchange for inverse drug discovery
2020 StandoutNobel
Procedures for large-scale metabolic profiling of serum and plasma using gas chromatography and liquid chromatography coupled to mass spectrometry
2011 Standout
Global metabolic profiling procedures for urine using UPLC–MS
2010 Standout
Update of randomized trials in recurrent disease
2011
Subtyping of triple‐negative breast cancer: Implications for therapy
2014
SuFEx Click Chemistry Enabled Late-Stage Drug Functionalization
2018 StandoutNobel
Photothermal therapy and photoacoustic imaging via nanotheranostics in fighting cancer
2018 Standout
New insights into the molecular and cellular functions of poly(ADP-ribose) and PARPs
2012
Olaparib: an oral PARP-1 and PARP-2 inhibitor with promising activity in ovarian cancer
2015
Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action
2016
Fulvestrant 500 mg Versus Anastrozole 1 mg for the First-Line Treatment of Advanced Breast Cancer: Overall Survival Analysis From the Phase II FIRST Study
2015
Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor
2012
Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas
2016 Standout
Chromone: A Valid Scaffold in Medicinal Chemistry
2014 Standout
Breast Cancer Treatment
2019 Standout
Statistical Methods for Handling Unwanted Variation in Metabolomics Data
2015
New Strategies in the Treatment of Ovarian Cancer: Current Clinical Perspectives and Future Potential
2013
Synergistic interaction between cisplatin and PARP inhibitors in non-small cell lung cancer
2013
UPLC-MS-Based Analysis of Human Plasma for Metabonomics Using Solvent Precipitation or Solid Phase Extraction
2009
The genesis and evolution of high-grade serous ovarian cancer
2010
Cancer Genome Landscapes
2013 StandoutScience
AAV9 delivering a modified human Mullerian inhibiting substance as a gene therapy in patient-derived xenografts of ovarian cancer
2015
Hypoxia-inducible factor 1-dependent expression of platelet-derived growth factor B promotes lymphatic metastasis of hypoxic breast cancer cells
2012 StandoutNobel
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 Mutation
2014 Standout
Development of a Robust and Repeatable UPLC−MS Method for the Long-Term Metabolomic Study of Human Serum
2009
Applications of Fluorine in Medicinal Chemistry
2015 Standout
A Randomized Phase II Study of Veliparib with Temozolomide Or Carboplatin/Paclitaxel Versus Placebo with Carboplatin/Paclitaxel in Brca1 / 2 Metastatic Breast Cancer: Design and Rationale
2016
Molecular Origin of Blood‐Based Infrared Spectroscopic Fingerprints**
2021 StandoutNobel
Identification and use of biomarkers in treatment strategies for triple‐negative breast cancer subtypes
2013
MetaboAnalyst 5.0: narrowing the gap between raw spectra and functional insights
2021 Standout
Works of Euan Macpherson being referenced
Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study
2011
Safety and tolerability of the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib (AZD2281) in combination with topotecan for the treatment of patients with advanced solid tumors: a phase I study
2011
Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer
2012 Standout
Evaluation of the repeatability of ultra-performance liquid chromatography–TOF-MS for global metabolic profiling of human urine samples
2008
Phase II randomized placebo-controlled study of olaparib (AZD2281) in patients with platinum-sensitive relapsed serous ovarian cancer (PSR SOC).
2011
Can we define tumors that will respond to PARP inhibitors? A phase II correlative study of olaparib in advanced serous ovarian cancer and triple-negative breast cancer.
2010
Activity of Fulvestrant 500 mg Versus Anastrozole 1 mg As First-Line Treatment for Advanced Breast Cancer: Results From the FIRST Study
2009
Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer (SOC) and a BRCA mutation (BRCAm).
2013